Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q2

4564.TEDINET S100S8MF
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥356m2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥515m2022-04-01 → 2022-09-30Cons.Net sales
Operating income−¥695m2023-04-01 → 2023-09-30Cons.Operating income
Operating income−¥618m2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income−¥708m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income−¥1.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥644m2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥709m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax−¥613m2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥711m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.1bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥614m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥711m2023-04-01 → 2023-09-30Cons.Profit loss
Net income−¥614m2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥1.2bnat 2023-09-30Cons.Assets
Total assets¥1.5bnat 2023-03-31Cons.Assets
Total assets¥1.7bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥233mat 2023-09-30Cons.Liabilities
Total liabilities¥656mat 2023-03-31Cons.Liabilities
Net assets / equity¥935mat 2023-09-30Cons.Net assets
Net assets / equity¥855mat 2023-03-31Cons.Net assets
Net assets / equity¥1.3bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥881mat 2023-09-30Cons.Cash and deposits
Cash and deposits¥1.1bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥881mat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥1.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.8bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥880m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥795m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥517m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥34m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥20m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥677m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥96m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-3.422023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.452023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.812022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.192022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.742022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio73.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio51.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio76.3%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥183m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥109m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥537,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥387,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥149,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥403m
—segment totalrevenue2023-04-01 → 2023-09-30¥357m
—segment totalrevenue external2023-04-01 → 2023-09-30¥356m
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥149,000
—segment totalsegment profit2023-04-01 → 2023-09-30−¥512m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥188m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥48m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥111,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-09-30−¥382m
—segment totalrevenue2022-04-01 → 2022-09-30¥515m
—segment totalrevenue external2022-04-01 → 2022-09-30¥515m
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥111,000
—segment totalsegment profit2022-04-01 → 2022-09-30−¥430m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 421
ItemContextValueUnit
Xbrl amendment flagFilingDateInstantfalse
Business results of group (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Business risks (text)FilingDateInstantText · Plus
Material matters relating to going concern etc business risks (text)FilingDateInstantText · Plus
Management analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Total number of shares (text)FilingDateInstantText · Plus
Issued shares total number of shares etc (text)FilingDateInstantText · Plus
Class issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)普通株式
Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registeredFilingDateInstant_OrdinaryShareMember
Original text (Japanese) 東京証券取引所 グロース市場
Description issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)単元株式数は100株であります。
Details of employee share option program (text)FilingDateInstantText · Plus
Other information on share acquisition rights (text)FilingDateInstantText · Plus
Exercises etc of moving strike convertible bonds etc (text)FilingDateInstantText · Plus
Changes in number of issued shares stated capital etc (text)FilingDateInstantText · Plus
Major shareholders (text)FilingDateInstantText · Plus
Name major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)中村　祐輔
Address major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)東京都目黒区
Name major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)特定有価証券信託受託者株式会社SMBC信託銀行
Address major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)東京都千代田区丸の内１－３－２
Name major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)中鶴　修一
Address major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)埼玉県さいたま市中央区
Name major shareholdersCurrentQuarterInstant_No4MajorShareholdersMember
Original text (Japanese)古川　洋一
Address major shareholdersCurrentQuarterInstant_No4MajorShareholdersMember
Original text (Japanese)東京都品川区
Name major shareholdersCurrentQuarterInstant_No5MajorShareholdersMember
Original text (Japanese)BNP PARIBAS ARBITRAGE SNC（常任代理人　BNPパリバ証券株式会社）
Address major shareholdersCurrentQuarterInstant_No5MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)荒川　博文
Address major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)東京都中央区
Name major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)JPモルガン証券株式会社
Address major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)東京都千代田区丸の内２－７－３
Name major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)楽天証券株式会社
Address major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)東京都港区南青山２－６－２１
Name major shareholdersCurrentQuarterInstant_No9MajorShareholdersMember
Original text (Japanese)BNY GCM ACCOUNTS M NOM（常任代理人　株式会社三菱UFJ銀行）
Address major shareholdersCurrentQuarterInstant_No9MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)北村　和子
Address major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)群馬県太田市
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithFullVotingRightsOtherMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesLessThanOneUnitMember－
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcCurrentQuarterInstant_Row1Member－
Address of shareholder treasury shares etcCurrentQuarterInstant_Row1Member－
Information about officers (text)FilingDateInstantText · Plus
Regulations in accordance with which consolidated financial statements have been prepared financial informationCurrentYTDDurationText · Plus
Note on independent audit financial informationCurrentYTDDurationText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass